Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly

Journal of Infectious Diseases

Volumn 173, Issue 2, 1996, Pages 387-393

  Sankilampi, Ulla ^a   Honkanen, Pekka O ^b   Bloigu, Aini ^b   Herva, Elja ^b   Leinonen, Maija ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0030052761     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.2.387     Document Type: Article

References (20)

1. Örtqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990;3:1105-13.
2. Venkatesan P, Gladman J, Macfarlane JT, et al. A hospital study of community acquired pneumonia in the elderly. Thorax 1990;45:254-8.
3. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88.
4. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
5. Nissinen A, Leinonen M, Huovinen P, et al. Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990. Clin Infect Dis 1995;20:1275-80.
6. Centers for Disease Control. Pneumococcal polysaccharide vaccine. MMWR 1989;38:73-6.
7. Fedson DS, Shapiro ED, LaForce FM, et al. Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med 1994;154:2531-5.
8. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration cooperative study. N Engl J Med 1986;315:1318-27.
9. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WFI. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;106:1-6.
10. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
11. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270:1826-31.
12. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
13. Lee CJ, Banks SD, Li JP. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Crit Rev Microbiol 1991;18:89-114.
14. Bruyn GA, Zegers BJ, van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin Infect Dis 1992;14:251-62.
15. Musher DM, Johnson B Jr, Watson DA. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun 1990;58:3871-6.
16. Sörensen UB, Henrichsen J. C-polysaccharide in a pneumococcal vaccine. Acta Pathol Microbiol Immunol Scand [C] 1984;92:351-6.
17. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986;154:245-56.
18. Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J Infect Dis 1990;161:736-40.
19. Koskela M. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr Infect Dis J 1987;6:519-26.
20. Vitharsson G, Jonsdottir I, Jonsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis 1994;170:592-9.